Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for cardiac fibrosis biomarkers in HFpEF
IRCT20230528058311N2Phase 3Recruiting
- Sponsor
- Jiroft University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Jiroft University of Medical Sciences. Primary endpoints: Change in serum galectin-3 and Change in serum sST2. Started Aug 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on IRCT20230528058311N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230528058311N2.